A5074555611- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Insect Resistance and Genetics
- Biosimilars and Bioanalytical Methods
- MicroRNA in disease regulation
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- Cancer-related molecular mechanisms research
- Occupational and environmental lung diseases
- Effects of Radiation Exposure
- Genetic Syndromes and Imprinting
- Epigenetics and DNA Methylation
- Immune Cell Function and Interaction
- Pleural and Pulmonary Diseases
- T-cell and B-cell Immunology
- Circular RNAs in diseases
University of Pennsylvania
2021-2024
Asbestos Diseases Research Institute
2019
The University of Western Australia
2019
The University of Queensland
2015
Hospital for Sick Children
2011
Toronto General Hospital
2011
SickKids Foundation
2011
Abstract We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, N = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects measurable disease, 10 exhibited partial...
Abstract Although monoallelic expression (MAE) is a frequent genomic event in normal tissues, its role tumorigenesis remains unclear. Here we carried out single-nucleotide polymorphism arrays on DNA and RNA from large cohort of pediatric adult brain tumor tissues to determine the genome-wide rate MAE, specific cancer-related genes, clinical consequences MAE tumors. We also used targeted genotyping examine tumor-related genes development specifically examined at TP53 IDH1. The was higher than...
The success of chimeric antigen receptor T cell therapies targeting solid tumors is limited by the immunosuppressive tumor microenvironment. We demonstrate that endowing CAR cells with ectopic interleukin-9 (IL-9) signaling co-expressing an IL-9 receptor, rewires fate under stress to enhance anti-tumor efficacy. In preclinical models, IL-9-signaling exhibit increased expansion, persistence, and infiltration, resulting in superior control at significantly lower doses than conventional...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...
<h3>Background</h3> There is an urgent need for treatment advancements in pancreatic ductal adenocarcinoma (PDAC), as current chemotherapy regimens and novel immunotherapeutic approaches have shown limited efficacy.<sup>1</sup> Mesothelin (MSLN) a promising target CAR T cell therapies PDAC due to its high expression. However, therapy has efficacy solid tumors, partly the acquisition of dysfunctional phenotype upon chronic antigen exposure.<sup>2</sup> Strategies overcome such are essential...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...
<h3>Background</h3> This study explores the synergistic potential of combining mouse mesothelin-specific chimeric antigen receptor (mmeso-CAR) T cells and a CD40 agonist (αCD40) to enhance CAR cell overall immune response against pancreatic ductal adenocarcinoma (PDAC) in syngeneic models. <h3>Methods</h3> The subcutaneous PDAC model was established using KPC-derived line. Mice were treated with mmeso-CAR cells, αCD40, or combinations both. In vivo therapeutic efficacy evaluated endpoint...